Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET

Company Participants

David Connolly - IR & Corporate Communications
David Meeker - Chairman, CEO & President
Jennifer Lee - EVP & Head, North America
Hunter Smith - CFO
Yann Mazabraud - EVP & Head, International

Conference Call Participants

Jeff Hung - Morgan Stanley
Phil Nadeau - TD Cowen
Whitney Ijem - Canaccord Genuity
Dae Gon Ha - Stifel
Corinne Johnson - Goldman Sachs
Tazeen Ahmad - BofA Securities
Joseph Stringer - Needham & Company
Michael Higgins - Ladenburg Thalmann

Operator

Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, David Connolly, Investor Relations and Corporate Communications. Sir, please go ahead.

David Connolly

Thank you, Michelle.

I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section on the Investors page of our website, ir.rhythmtx.com. This morning, we issued our press release that provides our second quarter 2024 financial results and business update, and that is available on our website.

Listed on Slide 2 is our agenda. On the call are David Meeker, our Chairman and Chief Executive Officer and President; Jennifer Lee, Executive Vice President, Head of North America; Hunter Smith, our Chief Financial Officer; and Yann Mazabraud, Executive Vice President, Head of International, is on the line joining us from Europe.

And on Slide 3, I'll remind you this call contains remarks concerning